Shire sells Daytrana rights back to Noven; Gilead discloses possible FDA warning on plant;

@FiercePharma: Top 10 Generic Drug Companies 2010. Report | Follow @FiercePharma

> Study: Device errors cost $1.1B annually. Report

> Shire is selling the global rights to Daytrana, its patch for attention deficit hyperactivity disorder, back to the treatment's developer and manufacuturer, Noven Pharmaceuticals. News

> New DNA tests aim to detect colon cancer early. Article

> Maintenance and procedural problems at a Gilead Sciences manufacturing and distribution facility could bring a warning letter from the FDA, the company disclosed. Report

> Pfizer won a ruling throwing out a claim by a woman who claims she suffered injuries as a result of taking the anti-epilepsy drug Neurontin. Story

> Alzheimer's biomarkers found in spinal fluid. Report

> Bisphosphonates, a class of medicines widely used to prevent bone loss, don't increase the risk of cancer of the esophagus or stomach, a study found. Article

> Genentech, a member of the Roche Group, got the FDA nod for a longer length of therapy for Valcyte in adult kidney transplant patients at high risk for cytomegalovirus disease. Item

> Some patients with congestive heart failure are not receiving recommended medicines that could keep them alive longer and out of the hospital, a trend that may be adding to the nation's health costs, U.S. researchers say. Report

Biotech News

 @FierceBiotech: Report: China readies $1.5B plan to bolster biotech. Article | Follow @FierceBiotech

 @JohnCFierce: SciClone says the feds are probing China activities; shares plunge 32 percent. News | Follow @JohnCFierce

> Developers zero in on the new 'bio-better' strategy. Report

> Dicerna bags $25M Series B for next-gen RNAi work. News

Medical Device News

> FAA fines Boston Scientific $91K for transport issues. Report

> Boston Sci gets document request from grand jury. Article

Drug Delivery News

> Researchers crack blood-brain barrier to treat tumors. Story

> Metal-packing nanoparticles treat cancer, useful for MRI. Item

> Elan's drug delivery unit takes on innovation. News

And Finally... A recent ruling on an obscure, 20-year-old tax dispute between Ottawa and GlaxoSmithKline is being hailed by tax lawyers as a victory that creates an important precedent for multinational clients in fights with the Canada Revenue Agency. Story

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.